TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult volunteers aged ≤ 90 years old, ≥18 years old；~* Conforming to the diagnostic criteria of cerebral infarction under the 2010 version of Chinese Guidelines for Treatment of Acute Ischemic Stroke；~* Conforming to diagnostic criteria of the stasis type of TCM on the ischemic stroke；~* The onset of acute cerebral infarction ≥ 10 days；~* Consciousness awake；~* Volunteers agree to accept the program and sign informed consent.~Exclusion Criteria:~* Excluding the patients of the yin deficiency type of ischemic stroke.The diagnostic criteria of Yin deficiency type of ischemic stroke is that sudden onset of disease；being signs or symptoms of of neurological deficit；CT or MRI examination showing intracranial ischemic lesions；Scarlet tongue；~* The volunteers with severe heart diseases, cardiac insufficiency, hepatosis, renal insufficiency, respiratory failure, malignant tumour, alimentary tract hemorrhage, etc. who may fail to complete the two-year follow-up；~* Psychiatric patients；~* Pregnants and lactating women；~* Volunteers in other clinical trials；~* Volunteers who are not suitable for this clinical trial according to the researchers for other reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Experimental group (Type: EXPERIMENTAL): On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Naoxintong capsule, 2 times a day, three granule per time
- Control group (Type: ACTIVE_COMPARATOR): On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Placebo capsule，which is identical with Naoxintong capsule in the appearance, shape, color and content, 2 times a day, three granule per time

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Male or female of at least 18 years of age and not more than 79 years of age at the time of signing informed consent - GHD diagnosed for at least 6 months (defined as 180 days) prior to screening - Treatment with hGH for at least 6 consecutive months (defined as 180 days) at screening - If applicable, hormone replacement therapies for any other hormone deficiencies, adequate and stable for at least 90 days prior to randomisation as judged by the investigator Exclusion Criteria: - Active malignant disease or history of malignancy. Exceptions to this exclusion criterion:1/ Resected in situ carcinoma of the cervix and squamous cell or basal cell carcinoma of the skin with complete local excision 2/ Subjects with GHD attributed to treatment of intracranial malignant tumours or leukaemia, provided that a recurrence-free survival period of at least 5 years is documented in the subject's medical records - For subjects with surgical removal or debulking of pituitary adenoma or other benign intracranial tumour within the last 5 years:Evidence of growth of pituitary adenoma or other benign intracranial tumour within the last 12 months (defined as below or equal to 365 days) before randomisation. Absence of growth must be documented by two post-surgery magnetic resonance imaging (MRI) scans or CT scans. The most recent MRI or CT scan must be performed below or equal to 9 months (defined as below or equal to 270 days) prior to randomisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Somapacitan (Type: EXPERIMENTAL): None
- Norditropin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations~* Body Mass Index (BMI) of 18 to 32 kg/m², inclusive~* Ages 18 to 55, inclusive~Exclusion Criteria:~* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population~* Major surgical procedure within 4 weeks prior to randomization~* Positive serology test for HIV, HBV or HCV~* Clinically significant history or presence of any of the following conditions: heart, liver, or kidney disease, neurologic or psychiatric disease~* History of gastrointestinal disease within the past 3 months~* Any clinically significant medical condition that could potentially affect your participation in the study and/or personal well-being, as judged by the investigator~* Donated blood or blood products to a blood bank, blood transfusion or participated in a clinical study (except a screening visit) requiring withdrawal of blood within 4 weeks prior to randomization~* Unable to tolerate oral and/or intravenous (IV) medications~* Unable to tolerate the puncturing of veins for drawing of blood~* Known allergy or hypersensitivity to any component of the study medication~* History of any significant drug allergies (such as anaphylaxis or hepatotoxicity)~* Used any prescription drugs or over the counter products to control acid (for example, Prevacid, Mylanta or Rolaids) within 4 weeks prior to randomization~* Used any other drugs including over the counter medications and herbal preparations within 1 week prior to randomization~* Taken any investigational drug or placebo (inactive drug) within 4 weeks prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 5 mg saxagliptin + 2 Glucophage XR 500 mg tablet (Type: EXPERIMENTAL): None
- FDC tablet (5 mg saxa + 1000 mg metformin XR) (single dose) (Type: EXPERIMENTAL): under fed state, single dose
- FDC tablet (5 mg saxa + 1000 mg metformin XR) (4 days) (Type: EXPERIMENTAL): under fed state, 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic ACL Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 and 89 years old~* Patients undergoing primary anterior cruciate ligament (ACL) reconstruction surgery~Exclusion Criteria:~* Patients below age 18 or above age 89~* Illiterate or non-English speaking individuals~* Patients with contraindications to Ketorolac~* History of chronic alcohol or drug abuse~* Chronic use of psychotropic or analgesic drugs~* Known peptic ulcer disease or bleeding diasthesis~* Renal dysfunction (estimated glomerular filtration rate \< 50 mL/min/1.73m2)~* Breastfeeding women~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: EXPERIMENTAL): Patients receive oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for pain following ACL reconstruction surgery
- Ketorolac (Type: EXPERIMENTAL): Patients receive IV ketorolac followed by ketorolac 10 mg every 6 hours for 3 days following ACL reconstruction surgery. Patients are additionally discharged with oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for additional pain control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient~* 18 years of age or older at Visit 1~* Diagnosis of Asthma~* Male or eligible Female~* Pre-bronchodilator FEV1 of 40-80% of the predicted normal value at Visit 1~* Demonstrated reversibility by ≥12% and ≥200mL of FEV1 within 40 minutes following albuterol at Visit 1~* A need for regular controller therapy (i.e., inhaled corticosteroids alone or in combination with a long-acting beta-agonist, or leukotriene modifier etc.,) for a minimum of 8 weeks prior to Visit 1.~Exclusion Criteria:~* History of Life threatening asthma~* Respiratory infection not resolved~* Asthma exacerbation~* Concurrent respiratory disease~* Current Smokers~* Other diseases that are uncontrolled disease or disease state that, in the opinion of the investigator, would put the safety of the patient at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study~* A positive Hepatitis B surface antigen or positive Hepatitis C antibody and/or HIV~* Visual clinical evidence of oropharyngeal candidiasis~* Drug or milk protein allergies~* Concomitant medications affecting course of asthma~* Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer)~* Previous use of GSK573719~* Any disease preventing use of anticholinergics~* Any condition that impairs compliance with study protocol including visit schedule and completion of daily diaries~* Any subject with a history of alcohol or substance abuse~* Any affiliation with Investigator's site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone Furoate (FF) (Type: ACTIVE_COMPARATOR): 100mcg, inhaled
- Fluticasone Furoate /Vilanterol (VI) (Type: ACTIVE_COMPARATOR): 100/25mcg inhaled
- Fluticasone Furoate/GSK573719 (Type: EXPERIMENTAL): 100/15.6-250mcg inhaled

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Long-Term Tolerability and Safety of Oral Prucalopride in Chronic Constipation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or non-pregnant, non-breast-feeding female outpatients of at least 18 years of age~2. Patient had completed the entire treatment period of the PRU-INT-6 study or the PRU-INT-12 study .~Exclusion Criteria:~1. Patients with impaired renal function~2. Patients with clinically significant abnormalities of haematology, urinalysis, or blood chemistry.~3. Females of child-bearing potential without adequate contraceptive protection during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* post-menopausal women, 50-85 years of age;~* any inflammatory rheumatoid disease including polymyalgia rheumatica;~* receiving treatment with 5-15 mg/day of prednisolone.~Exclusion Criteria:~* previous treatment with an iv bisphosphonate at any time;~* previous treatment with an oral bisphosphonate within the last 6 months, \>1 month of treatment within last year, or \>3 months of treatment within last 2 years;~* treatment with parathyroid hormone in last 2 years;~* inability to stand or sit in an upright position for at least 60 minutes;~* inability to swallow a tablet whole;~* history of major gastrointestinal disease.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ibandronate (Type: EXPERIMENTAL): Participants received monthly oral ibandronate (150 milligrams \[mg\]) for 12 months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received monthly oral placebo for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Health Effects of Indoor Air Filtration in Healthy Chinese Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy university students in Jiangwan Campus, Fudan university~* Non-smoking, no history of alcohol or drug abuse~* Free of chronic cardiovascular, respiratory, liver and kidney disease~* Spend at least 50% (weekdays) or 80% (weekends) of time indoors~Exclusion Criteria:~* Current or ever smokers~* History of asthma, chronic bronchitis，cough, hypertension or other chronic inflammatory disease~* acute infections~* medication use in recent one month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Air purifiers (Type: EXPERIMENTAL): Participants in this group received an intervention of true air purifiers placed in the center of the room.
- Control (Type: SHAM_COMPARATOR): Participants in this group received an intervention of sham air purifiers, which were under the same conditions as the true purifiers except the filter gauze in them were removed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitosterolemia Metabolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of homozygous sitosterolemia as established by genotyping and clinical parameters~Exclusion Criteria:~* pregnant~* intellectual disability~* major infectious diseases~* immunodeficiency~* cancer~* renal failure~* diabetes

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Ezetimibe (Type: EXPERIMENTAL): Compare on and off ezetimibe

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Essential hypertension with diastolic blood pressure 95-110 mmHg and systolic blood pressure \< 180 mmHg~* Previously untreated hypertension or treated with monotherapy (but not with ACE-inhibitors or Angiotensin II-receptor blockers)~* Impaired glucose tolerance or impaired fasting glucose (fasting plasma glucose; 6.1-7.0 mmol/l (110-126 mg/dl)~* Age over 18~* Informed consent~* Any one of these: Microalbuminuria (urin excretion \>20 microg/min), dyslipidemia (HDL-cholesterol \<0.9 mmol/l(35 mg/dl), Triglycerides \> 1.7 mmol/l (150 mg/dl), waist to hip-ratio \>0.9 in men and \>0.85 in women, BMI \>28 kg/m2.~Exclusion Criteria:~* Previous or current use of ACE-inhibitors or Angiotensin II-receptor blockers~* Previous or current antidiabetic medications~* Brittle pre-diabetes where the investigator anticipates pharmacological treatment within next 6 months~* Hypertensive patients where the investigator anticipates polytherapy within next 6 months~* Female patient who is pregnant or nursing or planning pregnancy within the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Web-based Bystander Education Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Student matriculated at Georgia State University~* Male~* 18 to 24~* Undergraduate~* Self-identify as heterosexual or bisexual~Exclusion Criteria:~* Graduate student~* Self-identify as homosexual

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- General Health promotion (Type: PLACEBO_COMPARATOR): A 3-hour general mental health web-based program.
- Bystander & Sexual Violence Prevention (Type: EXPERIMENTAL): A 3-hour web-based program designed to teach male college student bystanders to intervene.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological documented unresectable advanced (locally or metastatic) well or moderately differentiated neuroendocrine tumors of the lung or thymus (typical and atypical carcinoids according to the World Health Organisation (WHO) 2004 criteria);~* Imaging documented progression within 12 months before screening visit (V1), according to RECIST criteria v 1.1;~* Measurable disease, as defined by RECIST criteria v 1.1, on a CT scan performed at screening visit (V1);~* Octreoscan or Ga68-DOTA-TATE/TOC/NOC-PET-TC within 12 months before screening visit (V1);~* Adequate liver, renal and bone marrow function.~Exclusion Criteria:~* Poorly differentiated neuroendocrine carcinoma and mixed Neuroendocrine tumours (NET), according to WHO 2004 criteria~* Neuroendocrine tumours other than lung or thymus~* Non-neuroendocrine thymic neoplasm~* Received a prior therapy with Peptide Receptor Radionuclide Therapy (PRRT) within 6 months prior to screening visit (V1)~* Treated with systemic therapies (chemotherapy, interferon-alpha, somatostatin analogues, molecular target therapies) within 1 month prior to screening visit (V1)~* Treated with a number of systemic therapy lines \> 3 prior to screening visit (V1), and any of the following:~  1. for chemotherapy no more than 1 line prior to V1~ 2. for somatostatin analogue no more than 1 line therapy, considered as treatment lasting more than 6 months, prior to V1 no therapy with Temozolomide (TMZ) prior to V1~ 3. Received a prior therapy with Peptide Receptor Radionuclide Therapy (PRRT) within 6 months prior to screening visit (V1)~* Received external palliative radiotherapy within the last 28 days prior to screening visit (V1)~* Received locoregional therapies (Transarterial embolization, Transcatheter arterial chemoembolization, thermo-ablation with radio-frequency) and Selective internal radiotherapy within 3 months prior to screening visit (V1)~* Presence of symptomatic brain metastasis~* Subjects with symptomatic cholelithiasis at screening visit (V1)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lanreotide (Autogel formulation) and Temozolomide (Type: EXPERIMENTAL): Lanreotide ATG 120 mg every 28 days, deep subcutaneous injection for a maximum of 48 weeks, for a total number of 12 injections.~Temozolomide 250 mg hard capsules, for 5 consecutive days every 28 days, oral route, for a maximum of 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete